Supersaturated Drug Delivery System of Oxyberberine Based on Cyclodextrin Nanoaggregates: Preparation, Characterization, and in vivo Application

Today’s cyclodextrin is a fascinating practical application of CDs – how can we create a supersatured drug delivery system (SDDS)?

In this paper, Oxyberberine (OBB) – hydroxypropyl-β-CD SDDS was prepared using the ultrasonic-solvent evaporation method.

The oral relative bioavailability of OBB-HP-β-CD SDDS was also 16 times enhanced compared to that of the raw material. Finally, an in vivo pharmacodynamic assay showed that the anti-hyperuricemic potency of OBB-HP-β-CD SDDS was approximately 5– 10 times higher than that of OBB raw material.

Supersaturated drug delivery system of oxyberberine | IJN (dovepress.com)

CarboHyde blog, Supersaturated Drug Delivery System of Oxyberberine Based on Cyclodextrin Nanoaggregates: Preparation, Characterization, and in vivo Application

Evaluation of the performance of Hydroxypropyl-β-cyclodextrin for the consolidation of vegetable-tanned leather artifacts

Today’s cyclodextrin:
Hydroxypropyl-β-cyclodextrin for the consolidation of vegetable-tanned leather artifacts

The fragility and weakness of historical, archaeological, and heritage leather artifacts in museums, and libraries due to unsuitable environmental conditions are significant challenges.

Vegetable-tanned leather samples were treated with different concentrations of Hydroxypropyl Beta Cyclodextrin and subjected to artificial heat aging.

Results showed that Hydroxypropyl Beta Cyclodextrin at 1% and 2% concentrations improved chemical stability, surface morphology, color retention, and mechanical properties of the leather samples.

Evaluation of the performance of Hydroxypropyl-β-cyclodextrin for the consolidation of vegetable-tanned leather artifacts | Heritage Science | Full Text (springeropen.com)

CArboHyde blog

A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses

Scientists create first mouse model with complete, functional human immunesystem and a human-like gutmicrobiome that is capable of mounting specific antibody responses.

Such a model would have unlimited uses in pharma development. The work of Paolo Casali et al groundbreaking and will disrupt the animal models we use for efficacy and safety studies. How would you use this model first? I imagine studies with vaccines probably…

Nature Immunology, 5 July 2024

A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses | Nature Immunology

Carbohyde blog

Getting PFAS out of drinking water

Today’s cyclodextrin is C&EN‘s recent paper on PFAS removal out of drinking water features cyclodextrins too among other solutions.

The Chicago-based water purification company Cyclopure is looking beyond traditional activated carbon and ion-exchange resins. It uses β-cyclodextrins from plant-based products like corn and potato starch to remove PFAS from water.

For the past 4 years, the company has been optimizing conditions for polymerizing, purifying, and granulating β-cyclodextrins, which it purchases in bulk from WACKER. The plant-based sorbent, sold under the name Dexsorb, has a high capacity for PFAS, it takes up less space than GAC and can be regenerated.

Today, Cyclopure provides various industrial and consumer solutions with their technology

Public water utilities in the US are facing a 5-year deadline to meet low parts-per-trillion limits for six per- and polyfluoroalkyl substances (PFAS) in drinking water. The Environmental Protection Agency estimates that thousands of water systems will need to install advanced treatment processes to meet the limits. Utilities are eyeing several technologies to remove PFAS, including ion-exchange resins, granular activated carbon, and plant-based sorbents. But eventually they will need to replace such media, and what to do with the PFAS-laden spent media becomes the next challenge. Sustainability goals, concerns about liability related to PFAS in waste, and potential supply chain issues from soaring demand for PFAS removal media are pushing companies to develop methods for regenerating spent media and destroying the PFAS. But it’s unclear how water utilities will pay for technology to remove PFAS from their drinking water, as well as what the cost of replacing and disposing of media will be.

Getting PFAS out of drinking water (acs.org)

cyclopur

Cyclodextrin Magic: Safely Revitalize Your Hair Color with Cutting-Edge Technology

What a fascinating cyclodextrin application from L’Oréal. Formulations of a reducing agents and a cyclodextrins are proposed for removing color from keratin fibers such as hair.

This invention underlines the vast potential of CDs in cosmetic applications. If you would like to learn how you can develop a CD-based product yourself, this is the best place to look: Formulation development – www.carbohydesolutions.com

Link to patent: US20240197599 COMPOSITIONS AND METHODS FOR REMOVING COLOR FROM HAIR (wipo.int)

Anti–inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and combat inflammation

Today’s cyclodextrin is about the intrinsic anti-inflammatory properties of CDs.

Inflammation is an essential contributor to the pathophysiology of numerous diseases, and dysregulation of the involved signaling cascades often culminates in uncontrollable disease progression and, ultimately, chronification. Effectively addressing these disorders is challenging due to their inherent complexity and the need to mitigate inflammation while preserving essential immune functions.

Amphihilic cyclodextrin-based nanoparticles exhibit significant downregulation of crucial pro-inflammatory markers, along with changes in inflammasome activation and the lipid profile of pro-inflammatory macrophages after CD nanoparticle application. The findings of this study underscore the potential of cyclodextrin-based nanoparticles as versatile biomaterials for treating the complex pathophysiology of various acute and chronic inflammation-associated disorders.


Anti–inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and combat inflammation | Research Square
Felix E. B. Brettner, Annika Haessler, Jonas Schreiner et al from Goethe University Frankfurt

CarboHyde blog

P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

Today’s cyclodextrin: After a long time, HPBCD will be evaluated again in clinics, now in a new application.
ZyVersa Therapeutics Inc. is sponsoring this Phase 2a open-label, two- to three-center study to evaluate the clinical efficacy and safety of one dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes, diabetic kidney disease (DKD), and proteinuria.

According to the proposed mechanism of action, HPBCD entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.

Study Details | P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease | ClinicalTrials.gov


Insulin formulation and methods of using same in preterm infants

Today’s cyclodextrin is an excellent example of using CDs (in this particular case, HPBCD) in peptide/protein formulations. ELGAN Pharma‘s patent concerns combining insulin, cyclodextrins, and other components, where the role of the CD is stabilization and cryopreservation.

As we see more examples of CD-protein combinations in research and clinical practice, I am convinced that this use will shape future applications.

Espacenet – US2024165205A1

Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates with Different Payloads

Using cyclodextrins to prevent aggregation in protein formulations has been known for some time, and we have already published a lot about this topic.

This paper from Florian Johann, Steffen Wöll, and Henning Gieseler adds some special spice to the application as they investigate the potential of CDs in reducing aggregation of Antibody–Drug Conjugates with different payloads.

The main takeaways of the study are:

Hydroxypropylated (CDs) reduced agitation-induced aggregation in all tested ADCs without causing destabilization during incubation at 40 °C.

Native CDs that are not surface active partially reduced agitation-induced aggregation in ADCs, suggesting the possibility of stabilizing mechanisms beyond mere competition at the air-liquid interface.

ADC-specific formulation effects were observed, e.g., superior performance of the large HPγCD type in stabilizing a highly unstable ADC with a bulky fluorophore payload during incubation.

Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates with Different Payloads – ScienceDirect